AACR 2018: Anetumab Ravtansine Exhibits Additive Effects When Combined with PEGylated Doxorubicin, Bevacizumab, or Copanlisib in Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.